{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:31Z","timestamp":1792787851659,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the medical talents of Wuhan health and family planning commission","award":["2017[51]"],"award-info":[{"award-number":["2017[51]"]}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2017CFB567"],"award-info":[{"award-number":["2017CFB567"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stool DNA (sDNA) tests and fecal immunochemical test (FIT) are used for the detection of colorectal cancer (CRC). Here we performed a novel evaluation using sDNA and FIT to assess their performance in CRC screening and monitoring in Hubei, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Stool samples were collected from a high-risk population in Hubei, China (n\u2009=\u2009359). sDNA tests and FIT were performed to test for KRAS mutations, NDRG4 and BMP3 methylation, and check hemoglobin levels. The methylation in BMP3 and NDRG4 genes was detected by TaqMan PCR method from human fecal samples. KRAS gene mutation in human fecal DNA was tested using TaqMan probe and amplification-refractory mutation system method. The colloid gold method was used for detection of hemoglobin in fecal samples. Finally, a novel evaluation by software was used to calculate the comprehensive value of the combined results for CRC detection and monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The sensitivity and specificity of the novel evaluation for early CRC (stage I and II), advanced adenoma (AA), and non-colon cancer neoplasm (NA) detection were 95.45% and 81.6%, 29.63% and 75.9%, and 23.08% and 75.17%, respectively. The receiver operating characteristic (ROC) curves of the combined value for the above diseases were 0.945\u2009\u00b1\u20090.015, 0.543\u2009\u00b1\u20090.055, and 0.547\u2009\u00b1\u20090.038, respectively. The levels of the novel evaluation were not significantly associated with the pathology and stage (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). In 20 out of 22 CRC patients, the novel evaluation of sDNA and FIT had decreased below threshold (&lt;\u2009165) at after surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The novel evaluation with sDNA test and FIT has increased sensitivity for screening of CRC and AA. The novel evaluation may have potential importance as an indicator of early CRC. Additionally, the dynamic changes of the comprehensive value after surgery were correlated with CRC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-022-02470-z","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T09:03:54Z","timestamp":1660381434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Feasibility of quantification based on novel evaluation with stool DNA and fecal immunochemical test for colorectal cancer detection"],"prefix":"10.1186","volume":"22","author":[{"given":"Hongli","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"issue":"12","key":"2470_CR1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.14309\/ajg.0000000000000445","volume":"114","author":"LJW Bosch","year":"2019","unstructured":"Bosch LJW, Melotte V, Mongera S, et al. Multitarget stool DNA test performance in an average-risk colorectal cancer screening population. Am J Gastroenterol. 2019;114(12):1909\u201318.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2470_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/cam4.2735","volume":"9","author":"E D'Andrea","year":"2020","unstructured":"D\u2019Andrea E, Ahnen DJ, Sussman DA, et al. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality. Cancer Med. 2020;9(2):824\u201336.","journal-title":"Cancer Med"},{"issue":"3","key":"2470_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3322\/caac.21395","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177\u201393.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2470_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2470_CR5","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1002\/cam4.2896","volume":"9","author":"J Liu","year":"2020","unstructured":"Liu J, Huang X, Yang W, et al. Nomogram for predicting overall survival in stage II-III colorectal cancer. Cancer Med. 2020;9(7):2363\u201371.","journal-title":"Cancer Med"},{"issue":"5","key":"2470_CR6","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386.","journal-title":"Int J Cancer"},{"issue":"8","key":"2470_CR7","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/gutjnl-2018-317124","volume":"68","author":"H Chen","year":"2019","unstructured":"Chen H, Li N, Ren J, et al. Participation and yield of a population-based colorectal cancer screening programme in China. Gut. 2019;68(8):1450\u20137.","journal-title":"Gut"},{"issue":"1","key":"2470_CR8","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1186\/s12889-019-7318-8","volume":"19","author":"X Li","year":"2019","unstructured":"Li X, Zhou Y, Luo Z, et al. The impact of screening on the survival of colorectal cancer in Shanghai, China: a population based study. BMC Public Health. 2019;19(1):1016.","journal-title":"BMC Public Health"},{"key":"2470_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/CIA.S109285","volume":"11","author":"K Simon","year":"2016","unstructured":"Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967\u201376.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"2470_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12885-018-5232-6","volume":"19","author":"S van Rooijen","year":"2019","unstructured":"van Rooijen S, Carli F, Dalton S, et al. Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation. BMC Cancer. 2019;19(1):98.","journal-title":"BMC Cancer"},{"issue":"24","key":"2470_CR11","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319(24):2486\u201396.","journal-title":"JAMA"},{"issue":"20","key":"2470_CR12","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.3748\/wjg.v23.i20.3632","volume":"23","author":"M Navarro","year":"2017","unstructured":"Navarro M, Nicolas A, Ferrandez A, et al. Colorectal cancer population screening programs worldwide in 2016: an update. World J Gastroenterol. 2017;23(20):3632\u201342.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2470_CR13","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/ajg.2017.174","volume":"112","author":"DK Rex","year":"2017","unstructured":"Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. Am J Gastroenterol. 2017;112(7):1016\u201330.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2470_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clcc.2017.03.018","volume":"16","author":"J Zhang","year":"2017","unstructured":"Zhang J, Cheng Z, Ma Y, et al. Effectiveness of screening modalities in colorectal cancer: a network meta-analysis. Clin Colorectal Cancer. 2017;16(4):252\u201363.","journal-title":"Clin Colorectal Cancer"},{"issue":"14","key":"2470_CR15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1311194","volume":"370","author":"TF Imperiale","year":"2014","unstructured":"Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287\u201397.","journal-title":"N Engl J Med"},{"issue":"3","key":"2470_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1053\/j.gastro.2016.06.003","volume":"151","author":"U Ladabaum","year":"2016","unstructured":"Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. Gastroenterology. 2016;151(3):427-39.e6.","journal-title":"Gastroenterology"},{"issue":"3","key":"2470_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.7326\/M13-1484","volume":"160","author":"JK Lee","year":"2014","unstructured":"Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Internal Med. 2014;160(3):171.","journal-title":"Ann Internal Med"},{"issue":"22","key":"2470_CR18","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.3748\/wjg.v20.i22.6786","volume":"20","author":"G Binefa","year":"2014","unstructured":"Binefa G, Rodr\u00edguez-Moranta F, Teule A, et al. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20(22):6786\u2013808.","journal-title":"World J Gastroenterol"},{"key":"2470_CR19","doi-asserted-by":"publisher","first-page":"643136","DOI":"10.3389\/fonc.2021.643136","volume":"11","author":"S Mo","year":"2021","unstructured":"Mo S, Wang H, Han L, et al. Fecal multidimensional assay for non-invasive detection of colorectal cancer: fecal immunochemical test, stool DNA mutation, methylation, and intestinal bacteria analysis. Front Oncol. 2021;11:643136.","journal-title":"Front Oncol"},{"key":"2470_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13148-017-0426-3","volume":"9","author":"TJ Oh","year":"2017","unstructured":"Oh TJ, Oh HI, Seo YY, et al. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenet. 2017;9:126.","journal-title":"Clin Epigenet"},{"issue":"4","key":"2470_CR21","first-page":"504","volume":"16","author":"I Lansdorp-Vogelaar","year":"2018","unstructured":"Lansdorp-Vogelaar I, Goede SL, Bosch LJW, et al. Cost-effectiveness of high-performance biomarker tests vs fecal immunochemical test for noninvasive colorectal cancer screening. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018;16(4):504-12.e11.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"34","key":"2470_CR22","doi-asserted-by":"publisher","first-page":"e11817","DOI":"10.1097\/MD.0000000000011817","volume":"97","author":"S Sheng","year":"2018","unstructured":"Sheng S, Zhao T, Wang X. Comparison of robot-assisted surgery, laparoscopic-assisted surgery, and open surgery for the treatment of colorectal cancer: a network meta-analysis. Medicine. 2018;97(34):e11817.","journal-title":"Medicine"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02470-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02470-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02470-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T09:05:44Z","timestamp":1660381544000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02470-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2470"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02470-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"22 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with ethical guidelines and approved by the Ethics committee of Hubei Cancer Hospital (ethical approval number: 2018[31]). Written informed consent was obtained from individual.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors aren\u2019t employed by New Horizon Health Technology, China. The reagent kits ColoClear\u00ae in this research were supported by New Horizon Health Technology, China. The funding from the same company was paid for the fees for sample collection, medical examination of the subjects, colonoscopies and pathology. This arrangement has been reviewed and approved by the Hubei Cancer Hospital in accordance with its conflict of interest polices.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}